Skip to main content

Navigation group

Type at least 3 characters
708 articles

Articles

Methods

Published on 09 Nov 2022

Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies

in Gastrointestinal Cancers: Colorectal Cancer

  • Hiroshi Nakatsumi
  • Yoshito Komatsu
  • Tetsuhito Muranaka
  • Satoshi Yuki
  • Yasuyuki Kawamoto
  • Kazuaki Harada
  • Masayoshi Dazai
  • Miki Tateyama
  • Yusuke Sasaki
  • Takuto Miyagishima
Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies
Frontiers in Oncology
doi 10.3389/fonc.2022.939425
  • 2,175 views
  • 1 citation